The Role of APRIL in IgA Nephropathy

Despite optimized supportive care, many patients with immunoglobulin A (IgA) nephropathy have persistent proteinuria and remain at risk for end-stage kidney disease, highlighting the need for disease-modifying treatment that targets the immune-mediated cause of IgA nephropathy.¹ Based on evidence from genetic, animal, and clinical studies, APRIL plays a key role in the pathogenesis of IgA nephropathy.^2-4 Learn more about the role of APRIL in IgA nephropathy with this brief video.

References:

1. Gutiérrez E, Carvaca-Fontán F, Luzardo L, Morales E, Alonso M, Praga M. A personalized update on IgA nephropathy: a new vision and new future challenges. Nephron. 2020;144(11):551-571. doi: 10.1159/000509997
2. Myette JR, Kano T, Suzuki H, et al. A proliferation inducing ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy. Kidney International. 2019;96(1):104-116. doi: 10.1016/j.kint.2019.01.031
3. Mathur M, Chan TM, Oh K, et al. A proliferation-inducing ligand (APRIL) in the pathogenesis of immunoglobulin A nephropathy: a review of the evidence. J Clin Med. 2023;12(21):6927. doi: 10.3390/jcm12216927
4. Yeo SC, Barratt J. The contribution of a proliferation-inducing ligand (APRIL) and other TNF superfamily members in pathogenesis and progression of IgA nephropathy. Clin Kidney J. 2023;16(2):ii9-ii18. doi: 10.1093/ckj/sfad200

November 2024 US.UNB.X.24.00129